Literature DB >> 31436554

Cases Having a Gleason Score 3+4=7 With <5% of Gleason Pattern 4 in Prostate Needle Biopsy Show Similar Failure-free Survival and Adverse Pathology Prevalence to Gleason Score 6 Cases in a Radical Prostatectomy Cohort.

Shun Sato1, Takahiro Kimura2, Takashi Yorozu1, Hajime Onuma2, Kosuke Iwatani2, Shin Egawa2, Masahiro Ikegami1, Hiroyuki Takahashi1.   

Abstract

Recent discussions have suggested expanding the inclusion criteria for active prostate cancer surveillance to include cases with a Gleason score (GS) of 3+4=7. In this study, we examined this proposed use of a limited percent Gleason pattern 4 (%GP4) to identify candidates of active surveillance among 315 patients who underwent radical prostatectomy for prostate cancer with a GS of 6 or 3+4=7 via needle biopsy. The latter cases were divided into 4 groups using highest or overall %GP4 cut-off values of 5% and 10% as determined from prostate needle biopsies. The frequency of adverse pathology and risk of biochemical recurrence were compared between the GS 6 and both GS 3+4=7 groups. Adverse pathology was defined as a GS 4+3=7 or higher, pT3b staging or positive lymph node metastasis. Notably, the Gleason pattern 4 <5% and GS 6 groups did not differ significantly in terms of the frequency of adverse pathology and risk of biochemical recurrence by the highest method. However, other highest Gleason pattern 4 categories had significantly higher frequencies and risks. Using the overall method, even the Gleason pattern 4 <5% group had a significantly higher frequency of adverse pathology and risk of biochemical recurrence relative to the GS 6 group. In conclusion, our findings suggest that patients with a GS 3+4=7 on biopsy with a highest %GP4 <5% are similar candidates for active surveillance to men with GS 6 cancers.

Entities:  

Mesh:

Year:  2019        PMID: 31436554     DOI: 10.1097/PAS.0000000000001345

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  6 in total

1.  Combined MRI-targeted Plus Systematic Confirmatory Biopsy Improves Risk Stratification for Patients Enrolling on Active Surveillance for Prostate Cancer.

Authors:  Luke P O'Connor; Alex Z Wang; Nitin K Yerram; Amir H Lebastchi; Michael Ahdoot; Sandeep Gurram; Johnathan Zeng; Sherif Mehralivand; Stephanie Harmon; Maria J Merino; Howard L Parnes; Peter L Choyke; Baris Turkbey; Bradford J Wood; Peter A Pinto
Journal:  Urology       Date:  2020-07-15       Impact factor: 2.649

Review 2.  Active surveillance for intermediate-risk prostate cancer.

Authors:  Madhur Nayan; Filipe L F Carvalho; Adam S Feldman
Journal:  World J Urol       Date:  2022-01-19       Impact factor: 4.226

3.  Prostate cancer growth patterns beyond the Gleason score: entering a new era of comprehensive tumour grading.

Authors:  Geert J L H van Leenders; Esther I Verhoef; Eva Hollemans
Journal:  Histopathology       Date:  2020-09-13       Impact factor: 5.087

4.  Transition zone prostate cancer is associated with better clinical outcomes than peripheral zone cancer.

Authors:  Shun Sato; Takahiro Kimura; Hajime Onuma; Shin Egawa; Hiroyuki Takahashi
Journal:  BJUI Compass       Date:  2020-10-06

5.  The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma.

Authors:  Geert J L H van Leenders; Theodorus H van der Kwast; David J Grignon; Andrew J Evans; Glen Kristiansen; Charlotte F Kweldam; Geert Litjens; Jesse K McKenney; Jonathan Melamed; Nicholas Mottet; Gladell P Paner; Hemamali Samaratunga; Ivo G Schoots; Jeffry P Simko; Toyonori Tsuzuki; Murali Varma; Anne Y Warren; Thomas M Wheeler; Sean R Williamson; Kenneth A Iczkowski
Journal:  Am J Surg Pathol       Date:  2020-08       Impact factor: 6.298

6.  A critical evaluation of visual proportion of Gleason 4 and maximum cancer core length quantified by histopathologists.

Authors:  Lina Maria Carmona Echeverria; Aiman Haider; Alex Freeman; Urszula Stopka-Farooqui; Avi Rosenfeld; Benjamin S Simpson; Yipeng Hu; David Hawkes; Hayley Pye; Susan Heavey; Vasilis Stavrinides; Joseph M Norris; Ahmed El-Shater Bosaily; Cristina Cardona Barrena; Simon Bott; Louise Brown; Nick Burns-Cox; Tim Dudderidge; Alastair Henderson; Richard Hindley; Richard Kaplan; Alex Kirkham; Robert Oldroyd; Maneesh Ghei; Raj Persad; Shonit Punwani; Derek Rosario; Iqbal Shergill; Mathias Winkler; Hashim U Ahmed; Mark Emberton; Hayley C Whitaker
Journal:  Sci Rep       Date:  2020-10-14       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.